Dare Bioscience Files 8-K on Financials
Ticker: DARE · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1401914
Sentiment: neutral
Topics: financial-reporting, sec-filing, company-update
TL;DR
Dare Bioscience filed an 8-K for financial reporting. Nothing new disclosed in this snippet.
AI Summary
On March 28, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, including the submission of financial statements and exhibits. No specific new financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Dare Bioscience is providing updated financial information and exhibits to the SEC, which is standard for public companies and relevant for investors tracking their financial health.
Risk Assessment
Risk Level: low — The filing is a routine financial disclosure and does not appear to contain any new material negative information.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- Cerulean Pharma Inc. (company) — Former company name
- Tempo Pharmaceuticals Inc (company) — Former company name
- 3655 Nobel Drive, Suite 260, San Diego, CA 92122 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Dare Bioscience, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, including the submission of Financial Statements and Exhibits.
When was this 8-K report filed with the SEC?
This 8-K report was filed on March 28, 2024.
What is Dare Bioscience, Inc.'s principal executive office address?
Dare Bioscience, Inc.'s principal executive office is located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
Has Dare Bioscience, Inc. operated under any previous names?
Yes, Dare Bioscience, Inc. previously operated under the names Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
What is the SIC code for Dare Bioscience, Inc.?
The Standard Industrial Classification (SIC) code for Dare Bioscience, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-28 08:05:19
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 58KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-1_002.jpg (GRAPHIC) — 92KB
- 0001493152-24-011615.txt ( ) — 410KB
- dare-20240328.xsd (EX-101.SCH) — 3KB
- dare-20240328_lab.xml (EX-101.LAB) — 33KB
- dare-20240328_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: March 28, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-